Leaving no seizure undetected

image20
image21
image22
image23

The DisORDER

Epilepsy is a chronic, neurological disorder, which 

has been around for 3000 years, and causes unprovoked, recurrent seizures

with impacts ranging from social stigma, isolation, and injury including sudden death.

The Numbers

70 Million

People with epilepsy - globally

3.4 Million

People with Epilepsy in the US

150,000

New cases diagnosed annually in the US

40+

Seizure detection solutions to help patients improve quality of life

$15.5 Billion

Annual medical expenditures on Epilepsy in the US

The Problem

Existing Seizure Detection Methods are simply Insufficient

image24

Accurately detecting seizures outside of a hospital- based setting is like 

trying to diagnose a fever without a thermometer. We just don’t have the tools to do it well. 

The Solution

image25

Our seizure detection software software algorithm uses oculometric data (i.e, eye movements) to reliably detect a seizure.  By employing machine learning capabilities, our software will also be able to predict when a seizure will occur.  We expect our software to easily interface and/or integrate with other eye tracking systems (eg. smart glasses) and therapeutic devices (eg. neuromodulation).

The Competitive Advantage

It is expected that 100% of all seizures will be detected in an ambulatory setting

The Opportunity

Potentially, there are several opportunities to help revolutionize epilepsy care:

  • Eysz is expecting to quantitate in real time, side effects such as sedation and slowed cognition related to epilepsy and its treatment empowering patients and their physicians with data to make informed medical decisions. 
  • Eysz has the potential to alter the treatment landscape by collaborating with manufacturers of neuromodulation systems and pharmaceuticals for epilepsy. For example, Eysz has the potential to improve the biomarkers used in closed loop neuro-modulation systems such as the vagal nerve stimulator which currently rely on a heart rate, a biomarker which is approximately 70% accurate. 
  • Eysz has the potential to provide epileptic drug manufacturers with accurate seizure counts and side effect detection during clinical studies improving the quality of safety and efficacy data. 

The Preliminary Evidence

We recently completed a 30 patient proof-of-concept study which resulted in robust seizure detection of the subtlest seizure type, absence seizures.

Next Steps

We are planning to create eye-tracking wearables to be used in a clinical study within the next year....so stay tuned!

OUr Team

Rachel Kuperman, MD, CEO

image26

  Neurologist with dual certification in epilepsy and neurology with over 10 years’ experience directing the clinical epilepsy and research programs at UCSF Benioff Children’s Hospital, Oakland

Jit Sarkar, CTO

image27

 Leads the algorithm development for Eysz solution. He completed his undergraduate degree in computer science and has deep experience applying machine learning methods. His PhD from UCSD focused on extracting signals from a complex medium.

Nicolle Napier - Ionascu Chief Neuropsychologist

image28

Leads the Eysz cognitive research team. Practicing neuropsychology for over 12 years primarily in the Bay Area. She is also the head Neuropsychologist in the Epilepsy department at UCSF Benioff Children’s Hospital Oakland

Parth Amin, Director of Partnerships

image29

Experienced clinical device development and go-to-market strategist with 15+ years of global medical device and partnership experience. Currently develops and manages our partner ecosystem.

Robert Fisher, MD Scientific Advisory Board

image30

 Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford Epilepsy Center.   He had research awards from the Klingenstein Foundation, EF, CURE and  NIH. He published 160 peer-reviewed articles and 4 books. He was named  1996-2016 in Best Doctors in America.  He received the Ambassador Award  from the International League Against Epilepsy, the 2005 AES Service  Award and the 2006 Annual Clinical Research Award. 

Hal Blumenfeld, MD Scientific Advisory Board

image31

 Dr. Blumenfeld's clinical and research work focuses on epilepsy,  cognition and brain imaging. He directs Yale's Clinical Neuroscience  Imaging Center (CNIC), a new multi-disciplinary core facility for  innovative study and treatment of brain disorders. Teaching activities  include a textbook titled Neuroanatomy Through Clinical Cases, Sinauer  Assoc., Publ. 2002, 2010. 

Peter Milford, PhD Technical Advisory Board

image32

Dr. Milford has over 15 years experience in developing high technology instrumentation. He was CTO of Eyefluence, which was developing the next generation eye-tracking wearable technology,  up until October 2016, when purchased by Google. He  continued to develop eye interaction and eye tracking for augmented reality (AR) and virtual reality (VR) headsets.  He now serves as the President of Parallel Rules consulting firm. 

Steve Duddy Business Advisory Board

image33

Steve brings 30+ years of leadership and strategy experience in the Medical Device industry.  He has held a variety of leadership roles in various cross functional areas.  Most recently, he is serving as the President and Chairman of Nuvolase Inc., which has developed the gold standard for Onychomycosis.  Under his leadership, the company has grown in revenues, remained debt-free, and has expanded into new markets. 

Drop us a line with any questions, comments, or inquiries you may have or if you want to simply stay in touch.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.